

Cite this: *RSC Adv.*, 2018, 8, 14335

Substituted spirooxindole derivatives as potent anticancer agents through inhibition of phosphodiesterase 1†

Assem Barakat,^{ID}*^{ab} Mohammad Shahidul Islam,^{ID}^a Hussien Mansur Ghawas,^a Abdullah Mohammed Al-Majid,^a Fardous F. El-Senduny,^{ID}^c Farid A. Badria,^d Yaseen A. M. M. Elshaier^e and Hazem A. Ghabbour^{fg}

Spirooxindole is a promising chemo therapeutic agent. Possible targets include cancers of the liver, prostate, lung, stomach, colon, and breast. Here, we demonstrate a one-pot three-component reaction *via* a [3 + 2] cycloaddition/ring contraction sequence of a dipolarophile (activated alkene) with *in situ*-generated azomethine ylide (1,3-dipoles) without the use of any catalyst. The reaction provides efficient access to synthetically useful and biologically important spirooxindoles in high yield (69–94%) with high diastereoselectivity. The synthesized compounds were subjected to cytotoxicity evaluation using colorectal cancer (HCT-116), hepatocellular carcinoma (HepG2), and prostate cancer (PC-3) cells. Compounds **4i**, **4j**, and **4k** showed potent cytotoxic activity and high selectivity against HCT-116 cells when compared to cisplatin. Meanwhile compound **4d** retained high cytotoxic activity and selectivity against HepG2 and PC-3 cells in comparison to cisplatin. The mechanism of compound **4d** was further studied using phosphodiesterase 1 enzyme and showed 74.2% inhibitory activity. A possible binding mode for compound **4d** to PDE-1 was investigated by molecular modeling using OpenEye software. Pose predictions for the active compounds were demonstrated by ROCS alignments. Compound **4d** has a special geometry and differs from other active compounds.

Received 17th March 2018
Accepted 2nd April 2018

DOI: 10.1039/c8ra02358a

rsc.li/rsc-advances

1. Introduction

The combined therapy of a multi-kinase inhibitor and a specific phosphodiesterases (PDEs) inhibitor appears to be a good therapy option for tumor treatment, as the tumor growth is delayed and so the chance of survival is increased.¹ Phosphodiesterases (PDEs) are a ubiquitous family of enzymes that play a role in regulating the intracellular level of the second messengers cyclic adenosine monophosphate (cAMP) and cyclic

guanosine monophosphate (cGMP). PDEs are 11 isoenzymes (PDE1–PDE11) and their classification is based on their substrate, amino acid sequence, action or their distribution in the body. These enzymes are important regulators of signal transduction pathways regulating proliferation, apoptosis, differentiation, vasodilation, vasoconstriction and inflammation in cells. In breast and colon cancer cells, the increase in intracellular concentrations of cAMP may induce apoptosis, arrest growth, and reduce cell migration.²

PDE-1 catalyzes the hydrolysis of the phosphodiester bond between the catalytic tyrosine residue of topoisomerase I (TOP-1) and DNA 3'-phosphate during gene transcription.³ This makes PDE-1 a rational anticancer target. PDE-1 inhibitors have the potential to augment TOP-1 inhibitors as anticancer agents.⁴

Although high intracellular levels of cAMP can effectively inhibit the proliferation of cancer cells, compounds elevating cAMP are not recommended for use as anti-cancer drugs because of their high cytotoxicity.^{5–7} Limited numbers of PDE-1 inhibitors have been reported and there is still an unmet need to discover novel PDE-1 inhibitors.^{8,9} Several studies have been conducted *via* multidisciplinary international research groups to develop more selective and effective potential anti-cancer agents.^{10–17}

^aDepartment of Chemistry, College of Science, King Saud University, P. O. Box 2455, Riyadh 11451, Saudi Arabia. E-mail: ambarakat@ksu.edu.sa; Fax: +966-11467-5992; Tel: +966-11467-5901

^bDepartment of Chemistry, Faculty of Science, Alexandria University, P.O. Box 426, Ibrahimia, Alexandria 21321, Egypt

^cDepartment of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt

^dDepartment of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt

^ePharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Assuit 71524, Egypt

^fDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P. O. Box 2457, Riyadh 11451, Saudi Arabia

^gDepartment of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura 35516, Egypt

† Electronic supplementary information (ESI) available. CCDC 1583075 and 1818997. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c8ra02358a



Spirooxindoles have unique structural features and a ubiquitous class of biological activities, making them promising candidates for new drug discovery.¹⁸ Over the past decade, this class of compounds has enriched the repertoire of both oxindoles and other heterocyclic scaffolds and has attracted extensive research efforts from synthetic and medical chemists because of their unique chemopreventive properties.^{19–21} Two examples of representative spirooxindole-containing compounds are **NITD609** and **MI-888** (Fig. 1), which are currently in preclinical evaluation for the treatment of malaria and human cancer, respectively.^{22,23} On the other hand, naturally occurring spirocyclic oxindole alkaloids that could be isolated, such as **spirotryprostatins A** and **B**, also show excellent anticancer activities.²⁴ Additionally, spirooxindole-containing compounds have been reported to have antimycobacterial²⁵ or anti-inflammatory²⁶ activities, or can act as an acetylcholinesterase (AChE) inhibitors.^{27,28}

The importance of new anticancer agents originating from these spirooxindole architectures has stimulated our group into designing and synthesizing a new series of spirooxindoles **4a–n** through some modifications in the structure of reported drugs, especially **6SJ**^{29,30} (Fig. 1). These structural modifications include: (i) the substituted phenyl moiety tethered ring C was replaced with 3-acyl indole. This replacement is expected to increase the compound's potency, since this scaffold could form extra hydrogen bonding and hydrophobic–hydrophobic interactions. (ii) A substituted or non-substituted aryl group was also installed on ring C. This aryl arm was expected to switch the compound geometry and was suggested to be involved in extra ligand–receptor interactions. Based on the aforementioned information, and in continuation of our previous work,^{17,31–33} we synthesized biologically important, highly substituted, and functionalized spirooxindole derivatives, which are efficient and powerful agents for the treatment of cancer.

2. Results and discussion

2.1. Synthesis of 4a–n

Anticancer compounds incorporating oxindoles were synthesized using an efficient 1,3-dipolar cycloaddition reaction.^{17,31,32} The starting materials, α,β -unsaturated enone derivatives **1a–n** (Scheme 1), were synthesized by a condensation reaction of 3-acetyl indole with substituted aryl aldehydes in the presence of KOH in EtOH under reflux. Then, the one-pot reaction of α,β -unsaturated enone derivatives **1a–n** with *L*-proline **2** and isatin **3** was carried out at 60 °C in MeOH for 1.5–2.0 h to yield the final compound **4a–n**, with 4 stereogenic centers in good to excellent yield (69–94%). The molecular structure of the cycloadduct was confirmed by nuclear magnetic resonance (NMR) spectroscopic analysis. The reaction yielded the adduct **4a–n** as a single regioisomer. The structures of **4a–n** and their derivatives were deduced by ¹H-NMR, ¹³C-NMR, mass spectrometry (MS), infrared (IR) spectroscopy, elemental analysis, and X-ray crystallography. The absolute configurations for the desired compounds were assigned by X-ray, in addition to spectral analysis studies. The aryl moiety and acylindole originating from ring C were oriented as anti-conformation.

The proposed reaction mechanism of the three-component reaction is shown in Scheme 2. It was assumed that azomethine ylide was formed exclusively, possibly due to the nucleophilic attack of proline into the active carbonyl of isatin with conversion of the carbonyl group to alcohol. The resulting OH will attack the carboxylic group in proline to form a lactone functionality (intermediate **I**). *In situ* decarboxylation generates the reactive azomethine ylide. The reaction of olefin with azomethine ylide has four possibilities which will proceed regioselectively with path A exclusively and diastereoselectively with path C to furnish the final adduct (Table 1).^{34,35}




Fig. 1 Chemical structures of reported anticancer spirooxindoles and the modified spirooxindole (**4a–n**).







ORTEP of the synthesized compound **1a**Scheme 1 The synthesis of the target spirooxindole derivatives **4a-n**.Scheme 2 Plausible approach for the target compounds **4a-n**.

Table 1 Synthesis of spirooxindole-pyrrolidine 4a–n



Entry	4a–n	Ar	Yield (%)
1	4a	C ₆ H ₅	84
2	4b	<i>p</i> -MeC ₆ H ₄	92
3	4c	<i>p</i> -ClC ₆ H ₄	80
4	4d	2,4-Cl ₂ C ₆ H ₃	74
5	4e	<i>p</i> -MeOC ₆ H ₄	86
6	4f	<i>p</i> -BrC ₆ H ₄	77
7	4g	<i>p</i> -FC ₆ H ₄	84
8	4h	<i>m</i> -FC ₆ H ₄	78
9	4i	<i>m</i> -MeC ₆ H ₄	85
10	4j	<i>m</i> -BrC ₆ H ₄	72
11	4k	<i>p</i> -CF ₃ C ₆ H ₄	76
12	4l	2-Thiophene	94
13	4m	2-Furan	89
14	4n	3,4,5-Tri-MeOC ₆ H ₂	69

2.2. Biological activity

Fourteen compounds were tested against three common cancer cell lines, colorectal cancer (HCT-116), hepatocellular carcinoma (HepG2), and prostate cancer (PC-3). Interestingly, most

of the tested compounds showed a better selectivity index (SI: >1) over a commonly used chemotherapeutic drug (cisplatin, SI = 0.3). On the other hand, compounds 4i, 4j, and 4k showed a remarkable cytotoxicity against HCT-116 with SI > 2

Table 2 The cytotoxic activity and selectivity of the synthesized compounds against a colorectal cancer cell line (HCT-116)^a

Entry	4a–n	HCT-116 (IC ₅₀ , μM)	HCT-116 (IC ₅₀ , μg ml ⁻¹)	VERO-B (IC ₅₀ , μM)	SI*
1	4a	ND	ND	ND	ND
2	4b	21 ± 2	9.7	26	1.2
3	4c	20 ± 1.5	9.6	22	1.1
4	4d	9 ± 0.6	4.6	9	1
5	4e	26 ± 2	12.4	26	1
6	4f	21 ± 1.3	11	30	1.4
7	4g	16 ± 1	7.4	40	2.5
8	4h	15 ± 1.4	7	18	1.2
9	4i	7 ± 0.2	3.2	15	2.1
10	4j	9 ± 0.5	4.7	20	2.2
11	4k	9 ± 0.5	4.6	22	2.4
12	4l	50 ± 3.5	22.7	60	1.2
13	4m	29 ± 2	12.7	50	1.7
14	4n	20 ± 1.25	11.1	40	2
Positive control	Cisplatin	12.6 ± 0.40	3.8	5	0.4

^a SI*: selectivity index, ND: not determine.



Table 3 The cytotoxic activity and selectivity of the synthesized compounds against hepatocellular carcinoma (HepG2) cells^a

Entry	4a-n	HepG2 (IC ₅₀ , μM)	HepG2 (IC ₅₀ , μg ml ⁻¹)	VERO-B (IC ₅₀ , μM)	SI*
1	4a	ND	ND	ND	ND
2	4b	11.8 ± 2	5.4	26	2.2
3	4c	8 ± 0.5	3.8	22	2.8
4	4d	2 ± 0.1	1	9	4.5
5	4e	17.3 ± 3	8.3	26	1.5
6	4f	12 ± 1.5	6.3	30	2.5
7	4g	20 ± 2	9.3	40	2
8	4h	14 ± 0.22	6.5	18	1.3
9	4i	7 ± 0.40	3.2	15	2.1
10	4j	8 ± 1	4.2	20	2.5
11	4k	10 ± 1.25	5.2	22	2.2
12	4l	50 ± 3	22.7	60	1.2
13	4m	40 ± 5	17.5	50	1.3
14	4n	28 ± 2	15.7	40	1.4
Positive control	Cisplatin	5.5 ± 1.5	1.7	5	0.91

^a SI*: selectivity index, ND: not determine.

and IC₅₀ at 7, 9 and 9 μM, respectively, in comparison to 12.6 μM for cisplatin, as presented in Table 2.

Meanwhile, compound **4d** showed a remarkable cytotoxicity against HepG2 with SI greater than 4 and IC₅₀ at 2 μM *versus* 5.5 μM and SI less than 1 for the standard drug cisplatin, as presented in Table 3. In addition, compounds **4c**, **4i**, and **4j** presented similar cytotoxicity against HepG2 with IC₅₀ of 8, 7, and 8 μM, respectively, with a better SI > 2 (Table 3 and Fig. 2).

Interestingly, compound **4d** also showed superior cytotoxic activity against prostate cancer cells at IC₅₀ = 2 μM (Table 4), and its selectivity toward the cancer cells was greater than 4, which makes it a promising anticancer candidate. Despite that, compounds **4i**, **4j**, and **4k** showed anticancer activity at a higher IC₅₀ (7, 7, and 9 μM, respectively) but their selectivity index was still greater than 2 in comparison to the standard cisplatin (IC₅₀ at 5 μM and SI = 1) (Table 4).

2.3. Structural activity relationship (SAR)

The study of SAR showed that the *meta* substituted aromatic ring with either methyl or bromine led to an increase in the cytotoxicity of compounds **4i** (IC₅₀ = 7 μM) and **4j** (IC₅₀ = 9 μM), respectively, in comparison to the presence of a fluorine atom in

compound **4h** (IC₅₀ = 15 μM). Moreover, the presence of two chlorine atoms in compound **4d** at positions C-2 and C-4 in the aromatic ring greatly increased the anticancer activity (IC₅₀ = 2 μM) in comparison to one chlorine at the *para* position in compound **4c** (IC₅₀ = 8 μM). Also, SAR showed that the addition of trifluoromethyl at position C-4 rather than methoxy as in compound **4e** (IC₅₀ = 26 μM), bromine in compound **4f** (IC₅₀ = 21 μM) or fluorine in compound **4g** (IC₅₀ = 16 μM) improved the cytotoxicity of compound **4k** (IC₅₀ = 9 μM).

2.4. Phosphodiesterase inhibitory study

Due to the increase in tumor resistance after a refractory period, there has been extensive research to discover new leads to overcome the resistance and reduce the chemotherapeutic dose in order to decrease the side effects on normal cells. One way is to use phosphodiesterase 1 inhibitors in order to elevate the level of cAMP. Compound **4d**, which proved to be the most active and selective anticancer compound among all the tested compounds, showed remarkable inhibitory activity against phosphodiesterase enzyme (PD-1) at 2 μM with 74.2%. Compound **4d** could be used in combination with other anti-cancer drugs such as cisplatin for the treatment of solid tumors.




Fig. 2 Microscopic examination of the effect of compound **4i** on the growth of hepatocellular carcinoma (HepG2).



Table 4 The cytotoxic activity and selectivity of the synthesized compounds against prostate cancer cell line^a

Entry	4a–n	PC-3 (IC ₅₀ , μM)	PC-3 (IC ₅₀ , μg ml ⁻¹)	VERO-B (IC ₅₀ , μM)	SI*
1	4a	ND	ND	ND	ND
2	4b	16.3 ± 2	7.5	26	1.6
3	4c	11.8 ± 1.3	5.7	22	1.9
4	4d	2 ± 0.125	1	9	4.5
5	4e	15.5 ± 2	7.4	26	1.7
6	4f	16.3 ± 2.5	8.6	30	1.8
7	4g	16.3 ± 30	7.6	40	2.5
8	4h	11.5 ± 11.5	5.4	18	1.6
9	4i	7 ± 0.6	3.2	15	2.1
10	4j	7 ± 0.2	3.7	20	2.9
11	4k	9 ± 0.2	4.6	22	2.4
12	4l	29 ± 3	13	60	2.1
13	4m	26 ± 1.7	11.3	50	1.9
14	4n	17 ± 2	9.4	40	2.4
Positive control	Cisplatin	5 ± 0.45	1.5	5	1

^a SI*: selectivity index, ND: not determine.

It has been reported that the elevation of cAMP concentration in the cells leads to the inhibition of survival pathways such as MAPK³⁶ and antiapoptotic proteins like Bcl-2.³⁷ Furthermore, a high level of cAMP could inhibit the interaction of the tumor suppressor p53 protein with its regulator MDM-2.³⁸

2.5. Molecular docking and shape-matching studies

The crystallographic structure for PDE-1 illustrated that the active site region contains pairs of highly conserved histidine and lysine residues. The active site residues for catalysis are: His 263, Lys 265, His 493, and Lys 495.³⁹ The docking of these compounds with PDE-1 exhibited consensus scores and binding modes which correlated with their biological activity as anticancer agents. The target compounds were docked in the active site of PDE-1 (PDB: 1NOP) in order to investigate their

binding modes. A library of substituted spirooxindole compounds was designed and energy minimized using MMFF94 force field calculations for the catalytic domain of PDE-1 which was obtained from the protein data bank (PDB code: 1NOP)⁴⁰ and was prepared for docking using OpenEye® software.^{41,42}

Among all the compounds, compound **4d** showed the best consensus score of 19 by PDE-1 interaction. The pose and mode for compound **4d** bound to TDP1 are illustrated in Fig. 3. The carbonyl group of the oxindole scaffold forms hydrogen bonding (HB) interaction with the amino acid Thr 261. This interaction is near the amino acid His 263. The other carbonyl group that links the indole moiety with the remaining part of **4d** is also involved in HB interaction with the amino acid Ser 400. The indole part is incorporated near the amino acid Lys 495. The important pharmacophore 2,4-dichlorophenyl π -stacks inside the active site near Ser 463.

Finally, the indole moiety of the compound is directed toward the catalytic core of the enzyme through hydrophobic–hydrophobic interactions with His 493.




Fig. 3 Visual representation of **4d** docked with 1NOP showing two HB interactions and hydrophobic–hydrophobic interactions as shown by VIDA.




Fig. 4 ROCS run for compound **4d** with compounds **4k**, **4j** and **4i** with dissimilarity and not completely matched.



In order to understand the diversity of scaffolds in the most active compounds, ROCS alignments for our compounds was performed. ROCS is a fast shape comparison application. It uses a smooth Gaussian function to represent the molecular volume.⁴³ ROCS is useful in pose prediction in the absence of a protein structure.⁴⁴ Compound **4d** was selected as the query molecule. Other target compounds were selected as the database (dbase.fit) file. The ROCS run for compound **4d** with compounds **4k**, **4j** and **4i** represents a dissimilarity between **4d** and other compounds (Fig. 4).

For an explanation, compound **4d** exhibited a unique orientation in which the 2,4-dichlorophenyl moiety was located axially to the pyrrolidine moiety. The indole part is perpendicular to the oxindole moiety (Fig. 5). Superposition of compounds **4j** and **4k** (Fig. 6) indicates the chemical similarity between them as the *m*-Br phenyl and *p*-(CF₃) phenyl govern the molecular structure. The indole and oxindole moieties face each other with a buckled shape. Compound **4i** also adopts a buckled shape in which both indole and oxindole moieties face each other (Fig. 7) but it showed dissimilarities with compounds **4j** and **4k**.

3. Experimental

3.1. General procedure (GP1)

Enones **1a–p** (0.5 mmol), isatin (74 mg, 0.5 mmol) and L-proline (1.5 mmol) were dissolved in 20 ml of dry MeOH in a 50 ml round-bottom flask. Then, the reaction mixture was heated for 1.5–2 h at 60–65 °C. After the reaction was completed, as monitored by thin-layer chromatography (TLC), the crude material was subjected to column chromatography using ethyl acetate/*n*-hexane (2 : 3), yielding compounds **4a–n**.




Fig. 5 ROCS for **4d** with specific geometry of the 2,4-dichlorophenyl and indole moiety perpendicular to each other.




Fig. 6 Superposition for compounds **4j** and **4k** by ROCS exhibited structural similarity.

3.1.1. (2'*R*,3*S*,7*a'S*)-2'-(1*H*-Indole-3-carbonyl)-1'-phenyl-1',2',5',6',7',7*a'*'-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4a).** Yield, 84%; mp 171 °C; ¹H-NMR (400 MHz, DMSO-*d*₆) δ: 1.64–1.78 (m, 2H, CH₂), 1.82–1.90 (m, 2H, CH₂), 2.32–2.38 (m, 1H, CH₂), 2.48–2.58 (m, 1H, CH₂), 3.82–3.92 (m, 1H, CHN), 3.95




Fig. 7 ROCS for compound **4i** exhibited a buckled shape with a different pose inside the 1NOP.



(t, 1H, $J = 10.28$ Hz, CHPh), 4.61 (d, 1H, $J = 11.76$ Hz, CHCO), 6.53 (d, 1H, $J = 7.32$ Hz, Ar-H), 6.90 (t, 1H, $J = 7.32$ Hz, Ar-H), 6.92–7.04 (m, 2H, Ar-H), 7.08 (t, 1H, $J = 7.36$ Hz, Ar-H), 7.32 (d, 1H, $J = 8.04$ Hz, Ar-H), 7.36–7.47 (m, 4H, Ar-H), 7.78 (d, 1H, $J = 8.04$ Hz, Ar-H), 7.90 (d, 1H, $J = 2.92$ Hz, Ar-H), 10.27 (s, 1H, NH), 11.82 (s, 1H, NH); $^{13}\text{C-NMR}$ (100 MHz, DMSO- d_6) δ : 26.9, 29.7, 47.3, 51.5, 63.5, 71.3, 73.4, 109.5, 111.9, 116.7, 119.6, 120.9, 121.2, 121.6, 122.9, 125.1, 125.2, 127.8, 128.8, 129.9, 131.3, 133.5, 136.3, 139.8, 141.6, 179.8, 189; IR (KBr, cm^{-1}) $\nu_{\text{max}} = 3386, 3248, 2958, 2867, 1716, 1618, 1520, 1470, 1422, 1243, 1137, 1153, 748, 698$; [anal. calcd. for $\text{C}_{29}\text{H}_{25}\text{N}_3\text{O}_2$: C, 77.83; H, 5.63; N, 9.39; found: C, 77.75; H, 5.91; N, 9.49]; LC/MS (ESI, m/z): 447.20 [M + H] for 447.19 $\text{C}_{29}\text{H}_{25}\text{N}_3\text{O}_2$.

3.1.2. (2'R,3S,7a'S)-2'-(1H-indole-3-carbonyl)-1'-(p-tolyl)-1',2',5',6',7',7a'-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4b). Yield (92%); orange powder; mp 174–176 °C; $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ : 1.58–1.72 (m, 2H, CH_2), 1.73–1.86 (m, 2H, CH_2), 2.13 (s, 3H, CH_3), 2.25–2.34 (m, 1H, CH_2), 2.42–2.52 (m, 1H, CH_2), 3.78–3.83 (m, 1H, CH), 3.84 (t, 1H, $J = 12.08$ Hz, CH), 4.59 (d, 1H, $J = 11.00$ Hz, CH), 6.51 (d, 1H, $J = 7.36$ Hz, Ar-H), 6.88 (t, 1H, $J = 7.32$ Hz, Ar-H), 6.92–7.05 (m, 6H, Ar-H), 7.27 (d, 2H, $J = 8.80$ Hz, Ar-H), 7.34 (d, 1H, $J = 8.08$ Hz, Ar-H), 7.76 (d, 1H, $J = 8.04$ Hz, Ar-H), 7.87 (d, 1H, $J = 2.92$ Hz, Ar-H), 10.25 (s, 1H, NH), 11.78 (s, 1H, NH); $^{13}\text{C-NMR}$ (100 MHz, DMSO- d_6) δ : 20.6, 27.1, 30.1, 47.3, 52.0, 63.6, 71.6, 73.6, 109.6, 112.0, 117.0, 121.0, 121.3, 121.7, 122.9, 125.2, 125.5, 127.4, 127.9, 128.8, 129.1, 133.4, 135.7, 136.4, 137.3, 147.7, 180.1, 189.4; IR (KBr, cm^{-1}) $\nu_{\text{max}} = 3381, 3246, 2958, 2865, 1716, 1618, 1581, 1517, 1484, 1423, 1243, 1126, 749$; [anal. calcd. for $\text{C}_{30}\text{H}_{27}\text{N}_3\text{O}_2$: C, 78.07; H, 5.90; N, 9.10; found: C, 78.17; H, 5.82; N, 9.23]; LC/MS (ESI, m/z): 461.20 [M + H] for 461.21 $\text{C}_{30}\text{H}_{27}\text{N}_3\text{O}_2$.

3.1.3. (2'R,3S,7a'S)-1'-(4-chlorophenyl)-2'-(1H-indole-3-carbonyl)-1',2',5',6',7',7a'-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4c). Yield (80%); beige powder; mp: 165–167 °C; $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ : 1.60–1.74 (m, 2H, CH_2), 1.78–1.88 (m, 2H, CH_2), 2.28–2.36 (m, 1H, CH_2), 2.44–2.54 (m, 1H, CH_2), 3.78–3.88 (m, 1H, CH), 3.94 (t, 1H, $J = 10.24$ Hz, CH), 4.60 (d, 1H, $J = 11.72$ Hz, CH), 6.52 (d, 1H, $J = 8.08$ Hz, Ar-H), 6.89 (t, 1H, $J = 7.32$ Hz, Ar-H), 6.94–7.02 (m, 2H, Ar-H), 7.06 (t, 1H, $J = 7.32$ Hz, Ar-H), 7.30 (t, 3H, $J = 7.32$ Hz, Ar-H), 7.36 (d, 1H, $J = 7.36$ Hz, Ar-H), 7.45 (d, 2H, $J = 8.76$ Hz, Ar-H), 7.77 (d, 1H, $J = 7.32$ Hz, Ar-H), 7.89 (d, 1H, $J = 3.68$ Hz, Ar-H), 10.28 (s, 1H, NH), 11.82 (s, 1H, NH); $^{13}\text{C-NMR}$ (100 MHz, DMSO- d_6) δ : 27.0, 29.9, 47.36, 51.6, 63.6, 71.5, 73.5, 109.5, 112.0, 116.8, 121.0, 121.3, 121.7, 123.0, 125.2, 125.3, 127.9, 128.5, 128.9, 129.6, 131.3, 131.6, 136.4, 139.4, 141.7, 180.0, 189.2; IR (KBr, cm^{-1}) $\nu_{\text{max}} = 3247, 2959, 2928, 2868, 1713, 1619, 1521, 1492, 1470, 1424, 1334, 1243, 1138, 750, 532$; [anal. calcd. for $\text{C}_{29}\text{H}_{24}\text{ClN}_3\text{O}_2$: C, 72.27; H, 5.02; N, 8.72; found: C, 72.15; H, 5.13; N, 8.86]; LC/MS (ESI, m/z): 481.21 [M + H] for 481.16 $\text{C}_{29}\text{H}_{24}\text{ClN}_3\text{O}_2$.

3.1.4. (2'R,3S,7a'S)-1'-(2,4-dichlorophenyl)-2'-(1H-indole-3-carbonyl)-1',2',5',6',7',7a'-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4d). Yield, 74%; beige powder; mp: 149–151 °C; $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ : 1.68–1.82 (m, 2H, CH_2), 1.84–1.92 (m, 2H, CH_2), 2.34–2.42 (m, 1H, CH_2), 2.52–2.60 (m, 1H, CH_2), 3.52–3.62 (m, 1H, CHN), 3.80–3.88 (m, 1H, CHPh), 4.79 (d, 1H, $J = 11.72$ Hz, CHCO), 6.56 (d, 1H, $J = 7.36$ Hz, Ar-H),

6.92–7.11 (m, 4H, Ar-H), 7.34 (d, 2H, $J = 8.08$ Hz, Ar-H), 7.37 (d, 1H, $J = 2.20$ Hz, Ar-H), 7.57 (d, 1H, $J = 1.84$ Hz, Ar-H), 7.78 (t, 2H, $J = 10.24$ Hz, Ar-H), 7.96 (d, 1H, $J = 2.92$ Hz, Ar-H), 10.33 (s, 1H, NH), 11.86 (s, 1H, NH); $^{13}\text{C-NMR}$ (100 MHz, DMSO- d_6) δ : 26.9, 29.6, 47.2, 51.5, 63.1, 71.9, 73.4, 109.7, 111.8, 116.6, 121.1, 121.2, 121.7, 122.9, 125.0, 125.1, 127.4, 127.8, 128.8, 128.9, 129.0, 129.8, 131.7, 134.7, 136.4, 136.8, 141.8, 179.6, 188.9; IR (KBr, cm^{-1}) $\nu_{\text{max}} = 3255, 2964, 2869, 1711.1619, 1619, 1520, 1470, 1425, 1335, 1243, 1136, 1110, 1046, 749$; [anal. calcd. for $\text{C}_{29}\text{H}_{23}\text{Cl}_2\text{N}_3\text{O}_2$: C, 67.45; H, 4.49; N, 8.14; found: C, 67.55; H, 4.63; N, 8.02]; LC/MS (ESI, m/z): 515.10 [M + H] for 515.12 $\text{C}_{29}\text{H}_{23}\text{Cl}_2\text{N}_3\text{O}_2$.

3.1.5. (2'R,3S,7a'S)-2'-(1H-indole-3-carbonyl)-1'-(4-methoxyphenyl)-1',2',5',6',7',7a'-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4e). Yield (86%); yellow powder; mp: 122–124 °C; $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ : 1.64–1.76 (m, 2H, CH_2), 1.80–1.92 (m, 2H, CH_2), 2.30–2.38 (m, 1H, CH_2), 2.48–2.56 (m, 1H, CH_2), 3.52–3.58 (m, 1H, CH), 3.65 (s, 3H, OCH_3), 3.82–3.86 (m, 1H, CH), 3.89 (t, 1H, $J = 10.28$ Hz, CH), 4.58 (d, 1H, $J = 11.00$ Hz, CH), 6.53 (d, 1H, $J = 7.32$ Hz, Ar-H), 6.83 (d, 2H, $J = 8.80$ Hz, Ar-H), 6.91 (t, 1H, $J = 7.36$ Hz, Ar-H), 6.96–7.04 (m, 2H, Ar-H), 7.07 (t, 1H, $J = 7.32$ Hz, Ar-H), 7.31–7.38 (m, 4H, Ar-H), 7.79 (d, 1H, $J = 8.04$ Hz, Ar-H), 7.88 (d, 1H, $J = 2.92$ Hz, Ar-H), 10.25 (s, 1H, NH), 11.80 (s, 1H, NH); $^{13}\text{C-NMR}$ (100 MHz, DMSO- d_6) δ : 27.0, 29.9, 47.3, 51.47, 54.9, 63.6, 71.5, 73.4, 109.4, 111.9, 113.9, 116.9, 120.9, 121.3, 121.5, 122.9, 125.1, 125.4, 127.8, 128.5, 128.7, 132.1, 133.4, 136.3, 141.6, 157.9, 179.9, 189.3; IR (KBr, cm^{-1}) $\nu_{\text{max}} = 3387, 3247, 2960, 2868, 1713, 1618, 1513, 1469, 1437, 1244, 1178, 1138, 1034, 749$; [anal. calcd. for $\text{C}_{30}\text{H}_{27}\text{N}_3\text{O}_3$: C, 75.45; H, 5.70; N, 8.80; found: C, 75.31; H, 5.86; N, 9.03]; LC/MS (ESI, m/z): [477.20 [M + H] for 477.21 $\text{C}_{30}\text{H}_{27}\text{N}_3\text{O}_3$.

3.1.6. (2'R,3S,7a'S)-1'-(4-bromophenyl)-2'-(1H-indole-3-carbonyl)-1',2',5',6',7',7a'-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4f). Yield (77%); yellow powder; mp: 101–102 °C; $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ : 1.64–1.78 (m, 2H, CH_2), 1.82–1.92 (m, 2H, CH_2), 2.30–2.38 (m, 1H, CH_2), 2.49–2.58 (m, 1H, CH_2), 3.82–3.90 (m, 1H, CH), 3.95 (t, 1H, $J = 10.28$ Hz, CH), 4.64 (d, 1H, $J = 11.72$ Hz, CH), 6.53 (d, 1H, $J = 7.36$ Hz, Ar-H), 6.91 (t, 1H, $J = 8.04$ Hz, Ar-H), 6.95–7.02 (m, 1H, Ar-H), 7.07 (t, 1H, $J = 7.32$ Hz, Ar-H), 7.14 (t, 1H, $J = 7.36$ Hz, Ar-H), 7.26 (t, 2H, $J = 7.36$ Hz, Ar-H), 7.32 (d, 1H, $J = 8.08$ Hz, Ar-H), 7.37 (d, 1H, $J = 7.36$ Hz, Ar-H), 7.42 (d, 2H, $J = 6.60$ Hz, Ar-H), 7.78 (d, 1H, $J = 8.04$ Hz, Ar-H), 7.89 (d, 1H, $J = 2.92$ Hz, Ar-H), 10.26 (s, 1H, NH), 11.81 (s, 1H, NH); $^{13}\text{C-NMR}$ (100 MHz, DMSO- d_6) δ : 26.9, 29.9, 46.7, 52.1, 63.4, 71.6, 73.4, 109.4, 111.9, 116.8, 120.9, 121.2, 121.5, 122.8, 125.1, 125.4, 126.5, 127.6, 127.8, 128.4, 128.8, 133.4, 136.3, 140.4, 141.3, 179.9, 189.3; IR (KBr, cm^{-1}) $\nu_{\text{max}} = 3390, 3247, 2962, 2867, 1713, 1618, 1520, 1488, 1470, 1420, 1330, 1243, 1138, 1009, 749$; [anal. calcd. for $\text{C}_{29}\text{H}_{24}\text{BrN}_3\text{O}_2$: C, 66.17; H, 4.60; N, 7.98; found: C, 66.28; H, 4.51; N, 8.05]; LC/MS (ESI, m/z): 525.10 [M + H] for 525.11 $\text{C}_{29}\text{H}_{24}\text{BrN}_3\text{O}_2$.

3.1.7. (2'R,3S,7a'S)-1'-(4-fluorophenyl)-2'-(1H-indole-3-carbonyl)-1',2',5',6',7',7a'-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4g). Yield (84%); orange powder; mp: 144–146 °C; $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ : 1.62–1.76 (m, 2H, CH_2),



1.80–1.92 (m, 2H, CH₂), 2.30–2.38 (m, 1H, CH₂), 2.48–2.56 (m, 1H, CH₂), 3.80–3.98 (m, 2H, CH), 4.58 (d, 1H, *J* = 10.24 Hz, CH), 6.53 (d, 1H, *J* = 8.08 Hz, Ar-H), 6.81 (d, 1H, *J* = 8.08 Hz, Ar-H), 6.90 (t, 1H, *J* = 7.36 Hz, Ar-H), 6.96–7.11 (m, 4H, Ar-H), 7.28–7.33 (m, 3H, Ar-H), 7.35 (d, 1H, *J* = 6.60 Hz, Ar-H), 7.79 (d, 1H, *J* = 8.04 Hz, Ar-H), 7.88 (d, 1H, *J* = 2.92 Hz, Ar-H), 10.25 (s, 1H, NH), 11.79 (s, 1H, NH); ¹³C-NMR (100 MHz, DMSO-*d*₆) δ: 26.9, 30.64, 47.2, 51.3, 63.6, 71.4, 73.4, 109.4, 111.9, 114.3, 115.0, 115.3, 116.9, 120.9, 121.3, 121.5, 122.8, 125.1, 125.4, 127.8, 128.5, 128.7, 128.8, 129.5, 131.9, 133.3, 136.3, 141.6, 157.2, 179.9, 189.4; IR (KBr, cm⁻¹) ν_{max} = 3381, 3251, 2960, 2868, 1718, 1618, 1511, 1470, 1422, 1331, 1243, 1178, 1155, 1137, 1044, 861, 749; [anal. calcd. for C₂₉H₂₄FN₃O₂: C, 74.82; H, 5.20; N, 9.03; found: C, 75.02; H, 5.17; N, 9.11]; LC/MS (ESI, *m/z*): 465.20 [M + H] for 465.19 C₂₉H₂₄FN₃O₂.

3.1.8. (2'*R*,3*S*,7*a'S*)-1'-(3-Fluorophenyl)-2'-(1*H*-indole-3-carbonyl)-1',2',5',6',7',7*a'*-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4h).** Yield (78%); yellow powder; mp: 149–151 °C; ¹H-NMR (400 MHz, DMSO-*d*₆) δ: 1.58–1.72 (m, 2H, CH₂), 1.75–1.86 (m, 2H, CH₂), 2.24–2.34 (m, 1H, CH₂), 2.44–2.53 (m, 1H, CH₂), 3.79–3.86 (m, 1H, CH), 3.94 (t, 1H, *J* = 11.00 Hz, CH), 4.58 (d, 1H, *J* = 11.72 Hz, CH), 6.48 (d, 1H, *J* = 7.32 Hz, Ar-H), 6.85 (t, 1H, *J* = 8.08 Hz, Ar-H), 6.91–6.98 (m, 3H, Ar-H), 7.02 (t, 1H, *J* = 8.08 Hz, Ar-H), 7.20–7.26 (m, 4H, Ar-H), 7.33 (d, 1H, *J* = 7.32 Hz, Ar-H), 7.73 (d, 1H, *J* = 8.08 Hz, Ar-H), 7.89 (d, 1H, *J* = 3.68 Hz, Ar-H), 10.22 (s, 1H, NH), 11.78 (s, 1H, NH); ¹³C-NMR (100 MHz, DMSO-*d*₆) δ: 26.9, 29.7, 47.3, 51.8, 63.4, 71.3, 73.4, 109.5, 111.9, 113.3, 113.5, 114.4, 114.6, 116.7, 120.9, 121.2, 121.6, 122.9, 123.7, 125.1, 125.3, 127.8, 128.8, 130.3, 130.4, 133.7, 136.4, 141.7, 143.58, 161.0, 163.5, 179.8, 189.2; IR (KBr, cm⁻¹) ν_{max} = 3388, 3249, 2962, 2867, 1717, 1617, 1587, 1519, 1469, 1424, 1332, 1241, 1142, 748; [anal. calcd. for C₂₉H₂₄FN₃O₂: C, 74.82; H, 5.20; N, 9.03; found: C, 74.93; H, 5.09; N, 9.22]; LC/MS (ESI, *m/z*): 465.20 [M + H] for 465.19 C₂₉H₂₄FN₃O₂.

3.1.9. (2'*R*,3*S*,7*a'S*)-2'-(1*H*-Indole-3-carbonyl)-1'-(*m*-tolyl)-1',2',5',6',7',7*a'*-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4i).** Yield mg (85%); yellow powder; mp: 141–143 °C; ¹H-NMR (400 MHz, DMSO-*d*₆) δ: 1.62–1.72 (m, 2H, CH₂), 1.76–1.86 (m, 2H, CH₂), 2.20 (s, 3H, CH₃), 2.26–2.36 (m, 1H, CH₂), 2.46–2.52 (m, 1H, CH₂), 3.78–3.83 (m, 1H, CH), 3.87 (t, 1H, *J* = 9.52 Hz, CH), 4.60 (d, 1H, *J* = 11.00 Hz, CH), 6.49 (d, 1H, *J* = 7.32 Hz, Ar-H), 6.87 (t, 1H, *J* = 8.04 Hz, Ar-H), 6.91–7.00 (m, 2H, Ar-H), 7.03 (t, 1H, *J* = 8.04 Hz, Ar-H), 7.10 (t, 2H, *J* = 8.04 Hz, Ar-H), 7.14–7.24 (m, 2H, Ar-H), 7.28 (d, 1H, *J* = 8.08 Hz, Ar-H), 7.33 (d, 1H, *J* = 7.32 Hz, Ar-H), 7.74 (d, 1H, *J* = 8.08 Hz, Ar-H), 7.86 (d, 1H, *J* = 2.92 Hz, Ar-H), 10.21 (s, 1H, NH), 11.76 (s, 1H, NH); ¹³C-NMR (100 MHz, DMSO-*d*₆) δ: 21.0, 26.9, 29.9, 47.2, 52.1, 63.4, 71.6, 73.4, 109.4, 111.9, 116.8, 120.9, 121.2, 121.5, 122.8, 124.6, 125.1, 125.4, 127.2, 127.8, 128.3, 128.4, 128.7, 133.4, 136.3, 137.4, 140.3, 141.6, 180.1, 189.4; IR (KBr, cm⁻¹) ν_{max} = 3382, 3248, 2957, 2865, 1716, 1618, 1521, 1470, 1422, 1331, 1243, 1152, 1111, 749; [anal. calcd. for C₃₀H₂₇N₃O₂: C, 78.07; H, 5.90; N, 9.10; found: C, 77.89; H, 6.03; N, 9.15]; LC/MS (ESI, *m/z*): 461.20 [M + H] for 461.21 C₃₀H₂₇N₃O₂.

3.1.10. (2'*R*,3*S*,7*a'S*)-1'-(3-Bromophenyl)-2'-(1*H*-indole-3-carbonyl)-1',2',5',6',7',7*a'*-hexahydrospiro[indoline-3,3'-**

pyrrolizin]-2-one (4j). Yield (72%); yellow powder; mp: 110–112 °C; ¹H-NMR (400 MHz, DMSO-*d*₆) δ: 1.65–1.78 (m, 2H, CH₂), 1.82–1.92 (m, 2H, CH₂), 2.30–2.38 (m, 1H, CH₂), 2.50–2.57 (m, 1H, CH₂), 3.84–3.91 (m, 1H, CH), 3.97 (t, 1H, *J* = 10.24 Hz, CH), 4.62 (d, 1H, *J* = 11.72 Hz, CH), 6.52 (d, 1H, *J* = 7.36 Hz, Ar-H), 6.89 (t, 1H, *J* = 8.08 Hz, Ar-H), 7.00 (q, 2H, *J* = 7.32 Hz, Ar-H), 7.07 (t, 1H, *J* = 8.08 Hz, Ar-H), 7.24 (t, 2H, *J* = 8.08 Hz, Ar-H), 7.13–7.39 (m, 3H, Ar-H), 7.47 (d, 1H, *J* = 8.08 Hz, Ar-H), 7.65 (s, 1H, Ar-H), 7.77 (d, 1H, *J* = 7.32 Hz, Ar-H), 7.92 (d, 1H, *J* = 2.96 Hz, Ar-H), 10.26 (s, 1H, NH), 11.82 (s, 1H, NH); ¹³C-NMR (100 MHz, DMSO-*d*₆) δ: 26.8, 29.6, 47.3, 51.6, 63.5, 71.4, 73.4, 109.5, 111.9, 116.7, 120.9, 121.2, 121.6, 121.8, 122.9, 125.1, 125.2, 126.6, 127.8, 128.9, 129.5, 130.7, 130.8, 133.6, 136.3, 141.6, 143.3, 179.7, 189.1; IR (KBr, cm⁻¹) ν_{max} = 3403, 3253, 2958, 2866, 1715, 1619, 1520, 1470, 1424, 1332, 1241, 1134, 748; [anal. calcd. for C₂₉H₂₄BrN₃O₂: C, 66.17; H, 4.60; N, 7.98; found: C, 66.06; H, 4.49; N, 7.92]; LC/MS (ESI, *m/z*): 525.10 [M + H] for 525.11 C₂₉H₂₄BrN₃O₂.

3.1.11. (2'*R*,3*S*,7*a'S*)-2'-(1*H*-Indole-3-carbonyl)-1'-(4-[tri-fluoromethylphenyl]-1',2',5',6',7',7*a'*-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4k).** Yield (76%); yellow powder; mp: 153–155 °C; ¹H-NMR (400 MHz, DMSO-*d*₆) δ: 1.62–1.80 (m, 2H, CH₂), 1.82–1.93 (m, 2H, CH₂), 2.30–2.40 (m, 1H, CH₂), 2.50–2.58 (m, 1H, CH₂), 3.86–3.94 (m, 1H, CH), 4.07 (t, 1H, *J* = 11.00 Hz, CH), 4.67 (t, 1H, *J* = 11.76 Hz, CH), 6.53 (d, 1H, *J* = 7.36 Hz, Ar-H), 6.90 (t, 1H, *J* = 7.32 Hz, Ar-H), 6.95–7.07 (m, 3H, Ar-H), 7.33 (d, 1H, *J* = 5.84 Hz, Ar-H), 7.39 (d, 1H, *J* = 7.36 Hz, Ar-H), 7.55–7.72 (m, 4H, Ar-H), 7.76 (d, 1H, *J* = 8.08 Hz, Ar-H), 7.887791 (d, 1H, *J* = 3.68 Hz, Ar-H), 10.28 (s, 1H, NH), 11.83 (s, 1H, NH); ¹³C-NMR (100 MHz, DMSO-*d*₆) δ: 26.9, 29.7, 47.2, 51.8, 63.4, 71.4, 73.4, 79.1, 109.4, 111.9, 116.6, 120.9, 121.2, 121.6, 122.9, 125.0, 125.2, 125.3, 127.5, 127.6, 128.6, 128.8, 133.6, 136.3, 141.6, 145.3, 179.7, 189.0; IR (KBr, cm⁻¹) ν_{max} = 3254, 2960, 2869, 1716, 1619, 1521, 1470, 1423, 1325, 1165, 1116, 1068, 1017, 7450; [anal. calcd. for C₃₀H₂₄F₃N₃O₂: C, 69.89; H, 4.69; N, 8.15; found: C, 70.07; H, 4.82; N, 8.01]; LC/MS (ESI, *m/z*): 515.20 [M + H] for 515.18 C₃₀H₂₄F₃N₃O₂.

3.1.12. (2'*R*,3*S*,7*a'S*)-2'-(1*H*-Indole-3-carbonyl)-1'-(thiophen-2-yl)-1',2',5',6',7',7*a'*-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4l).** Yield (94%); yellow powder; mp: 157–159 °C; ¹H-NMR (400 MHz, DMSO-*d*₆) δ: 1.68–1.82 (m, 2H, CH₂), 1.82–1.91 (m, 1H, CH₂), 1.92–2.02 (m, 1H, CH₂), 2.28–2.38 (m, 1H, CH₂), 2.48–2.56 (m, 1H, CH₂), 3.88–3.98 (m, 1H, CH), 4.21 (t, 1H, *J* = 9.52 Hz, CH), 4.50 (d, 1H, *J* = 11.76 Hz, CH), 6.52 (d, 1H, *J* = 7.32 Hz, Ar-H), 6.89–6.92 (m, 2H, Ar-H), 6.96–7.03 (m, 3H, Ar-H), 7.11 (t, 1H, *J* = 6.60 Hz, Ar-H), 7.28 (d, 1H, *J* = 5.12 Hz, Ar-H), 7.32–7.35 (m, 2H, Ar-H), 7.82 (d, 1H, *J* = 8.08 Hz, Ar-H), 7.85 (d, 1H, *J* = 2.92 Hz, Ar-H), 10.27 (s, 1H, NH), 11.85 (s, 1H, NH); ¹³C-NMR (100 MHz, DMSO-*d*₆) δ: 26.9, 30.0, 47.3, 64.6, 64.9, 71.5, 73.5, 109.5, 111.9, 116.8, 120.9, 121.3, 121.6, 122.9, 123.9, 124.4, 125.0, 125.1, 126.9, 127.8, 128.9, 133.4, 136.4, 141.6, 143.4, 179.7, 188.9; IR (KBr, cm⁻¹) ν_{max} = 3382, 3250, 2963, 2963, 2867, 1717, 1620, 1521, 1469, 1426, 1332, 1421, 1132, 749, 698; [anal. calcd. for C₂₇H₂₃N₃O₂S: C, 71.50; H, 5.11; N, 9.26; found: C, 71.37; H, 4.97; N, 9.04]; LC/MS (ESI, *m/z*): 453.10 [M + H] for 453.10 C₂₇H₂₃N₃O₂S.



3.1.13. (2'R,3S,7a'S)-1'-(Furan-2-yl)-2'-(1H-indole-3-carbonyl)-1',2',5',6',7',7a'-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4m). Yield (89%); beige powder; mp: 172–174 °C; ¹H-NMR (400 MHz, DMSO-*d*₆) δ: 1.72–1.96 (m, 3H, CH₂), 2.00–2.10 (m, 1H, CH₂), 2.34–2.42 (m, 1H, CH₂), 2.48–2.54 (m, 1H, CH₂), 3.92–4.00 (m, 1H, CH), 4.09 (t, 1H, *J* = 9.56 Hz, CH), 4.65 (d, 1H, *J* = 11.72 Hz, CH), 6.24 (d, 1H, *J* = 2.88 Hz, Ar-H), 6.35 (t, 1H, *J* = 2.20 Hz, Ar-H), 6.57 (d, 1H, *J* = 7.32 Hz, Ar-H), 6.95 (t, 1H, *J* = 7.32 Hz, Ar-H), 7.06–7.10 (m, 2H, Ar-H), 7.16 (t, 1H, *J* = 7.32 Hz, Ar-H), 7.35 (d, 1H, *J* = 7.32 Hz, Ar-H), 7.42 (d, 1H, *J* = 8.04 Hz, Ar-H), 7.56 (d, 1H, *J* = 1.48 Hz, Ar-H), 7.88 (d, 1H, *J* = 8.04 Hz, Ar-H), 7.94 (d, 1H, *J* = 2.92 Hz, Ar-H), 10.32 (s, 1H, NH), 11.91 (s, 1H, NH); ¹³C-NMR (100 MHz, DMSO-*d*₆) δ: 26.9, 30.3, 45.4, 47.2, 61.2, 68.8, 73.2, 105.5, 109.5, 110.3, 111.9, 116.5, 120.9, 121.3, 121.6, 125.1, 125.2, 127.8, 128.8, 133.4, 136.8, 141.6, 141.9154.0, 179.6, 188.8; IR (KBr, cm⁻¹) ν_{max} = 3401, 3242, 2961, 2872, 1721, 1630, 1617, 1522, 1471, 1422, 1244, 1150, 1130, 1113, 1011, 751; [anal. calcd. for C₂₇H₂₃N₃O₃: C, 74.12; H, 5.30; N, 9.60; found: C, 73.98; H, 5.47; N, 9.51]; LC/MS (ESI, *m/z*): 437.20 [M + H] for 437.17 C₂₇H₂₃N₃O₃.

3.1.14. (2'R,3S,7a'S)-2'-(1H-Indole-3-carbonyl)-1'-(3,4,5-trimethoxyphenyl)-1',2',5',6',7',7a'-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one (4n). Yield (69%); yellow powder; mp: 179–181 °C; ¹H-NMR (400 MHz, DMSO-*d*₆) δ: 1.64–1.82 (m, 2H, CH₂), 1.82–1.94 (m, 2H, CH₂), 2.32–2.40 (m, 1H, CH₂), 2.50–2.58 (m, 1H, CH₂), 3.56 (s, 3H, OCH₃), 3.70–3.72 (m, 1H, CH), 3.74 (s, 6H, 2xOCH₃), 3.89–3.91 (m, 1H, CH), 4.64–4.67 (m, 1H, CH), 6.53 (d, 1H, *J* = 8.08 Hz, Ar-H), 6.73 (s, 2H, Ar-H), 6.91 (t, 1H, *J* = 7.32 Hz, Ar-H), 6.96–7.05 (m, 2H, Ar-H), 7.08 (t, 1H, *J* = 7.32 Hz, Ar-H), 7.33 (d, 1H, *J* = 8.04 Hz, Ar-H), 7.41 (d, 1H, *J* = 7.36 Hz, Ar-H), 7.79 (d, 1H, *J* = 8.04 Hz, Ar-H), 7.99 (d, 1H, *J* = 2.92 Hz, Ar-H), 10.23 (s, 1H, NH), 11.80 (s, 1H, NH); ¹³C-NMR (100 MHz, DMSO-*d*₆) δ: 26.9, 29.9, 47.3, 52.4, 55.8, 59.8, 63.2, 71.4, 73.6, 104.9, 109.4, 111.9, 116.9, 120.8, 121.2, 121.5, 122.8, 125.1, 125.4, 127.8, 128.7, 133.6, 136.0, 136.2, 136.4, 141.6, 152.8, 175.5, 189.4; IR (KBr, cm⁻¹) ν_{max} = 3256, 2937, 2870, 1720, 1619, 1590, 1510, 1468, 1427, 1332, 1243, 1187, 1154, 1126, 9997, 788, 743; [anal. calcd. for C₃₂H₃₁N₃O₅: C, 71.49; H, 5.81; N, 7.82; found: C, 71.35; H, 5.92; N, 7.96]; LC/MS (ESI, *m/z*): 537.20 [M + H] for 537.23 C₃₂H₃₁N₃O₅.

3.2. Anticancer activity

3.2.1. Cell lines and drugs. The cytotoxic activity of the compounds was tested against different mammalian cancer cells, prostate carcinoma cells (PC-3), hepatocellular carcinoma (HepG2) and colon cancer cells (HCT-116). African green monkey kidney cells (Vero-B) were used as normal cells to study the selectivity towards the cancer cells. The cell lines were obtained from the American Type Culture Collection (ATCC). The cells were cultivated at 37 °C and 10% CO₂ in DMEM (Lonza, Germany) medium supplemented with 10% fetal bovine serum (Lonza, Germany), 100 IU ml⁻¹ penicillin and 100 µg ml⁻¹ streptomycin (Lonza, Germany). Cisplatin (*cis*-diammineplatinum(II) dichloride) was used as a positive control and was obtained from Sigma-Aldrich®, then dissolved in 0.9% saline and stored as an 8 mM stock solution at –20 °C. The

spirooxindole derivatives were solubilized in DMSO and stored at –20 °C. The viability of the cells was quantified using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), which measures the activity of mitochondrial succinate dehydrogenase in viable cells.^{45,46}

3.2.2. Cytotoxicity assay. The cells were seeded in 96-well plates at a concentration of 5 × 10⁴ cells per ml (100 µl per well). A serial dilution of tested compounds or cisplatin was added after the cells were incubated overnight at 37 °C and under 5% CO₂. DMSO was used as a negative control (0.1%). The cells were incubated for 48 h. After that, 15 µl of MTT (5 mg ml⁻¹ in PBS) was added to each well and incubated for another 4 h. The formazan crystals were solubilized by 100 µl of acidified SDS solution (10% SDS/0.01 N HCl in PBS). The absorbance was measured after 14 h of incubation at 37 °C and under 5% CO₂ at 570 nm by using a BioTek microplate reader. Each experiment was repeated 3 times and a standard deviation was calculated (SD±). IC₅₀ was calculated as the concentration that caused 50% inhibition of cell growth. The growth of the cells was monitored and the images were acquired by Gx microscopes (GXMGXD202 Inverted Microscope) at 10× magnification.

3.2.3. Selectivity index (SI) calculations. The selectivity index was calculated with the following equation

$$SI = \frac{(IC_{50})_{normal}}{(IC_{50})_{cancer}} \quad (1)$$

Eqn (1): selectivity index (SI) equation: where IC₅₀ normal = the concentration of the tested compound that killed 50% of normal cells; IC₅₀ cancer = the concentration of the same tested compound that killed 50% of cancer cells.

3.2.4. Phosphodiesterase I inhibition assay. A phosphodiesterase I inhibition assay was performed using snake venom according to a previously reported method with minute variations. Briefly, 33 mM Tris-HCl buffer of pH 8.8 (97 µl), 30 mM magnesium acetate with an enzyme concentration of 0.000742 U well⁻¹ and 0.33 mM bis(*p*-nitrophenyl) phosphate (Sigma N-3002, 60 µl) as substrate were taken. EDTA with an IC₅₀ ± SD of 274 ± 0.007 µM was used as the positive control. After a pre-incubation period of 30 min, the enzyme with the test samples was observed spectrophotometrically for enzyme activity on a microtiter plate reader at 37 °C by following the rate of change in OD min⁻¹ at 410 nm of the *p*-nitrophenol released from *p*-nitrophenyl phosphate. All assays were processed in triplicate.⁴⁷

3.2.5. Docking studies. The docking studies were performed using OpenEye Modelling software. A virtual library of spirooxindoles derivatives was used and their energies were minimized using the MMFF94 force field, followed by the generation of multi-conformers using the OMEGA application.⁴² The whole library of minimized energy values was docked along with the prepared PDE-1 (PDB ID: 1NOP)^{40–48} using the FRED application to generate a physical property (Δ*G*) reflecting the predicted energy profile of the ligand-receptor complex. For ROCS study, the most active compound was selected as the query molecule. A library of compounds was adopted as the database (fit) file. The VIDA application⁴⁹ was employed as a visualization tool to show the poses of the ligands and the



potential binding interactions of the ligands to the receptor of interest.

4. Conclusions

In summary, inspired by synthesized spirooxindoles and natural architectures, we have succeeded in generating potent anticancer derivatives. The *in vitro* study revealed highly selective anticancer agents with a much better cytotoxic activity against colorectal cancer (HCT-116), hepatocellular carcinoma (HepG2), and prostate cancer (PC-3) when compared to the commonly used chemotherapeutic cisplatin. In the phosphodiesterase 1 enzyme inhibition studies, compound **4d** proved to exhibit a high cytotoxic activity against colorectal, prostate, and liver cancers at $IC_{50} = 9, 2, \text{ and } 2 \mu\text{M}$ with selectivity indices $>1, >4, \text{ and } >4$, respectively. Moreover, compound **4d** showed the best interaction with PDE-1 with a consensus score of 19. It formed two HB interactions and also hydrophobic interactions. The ROCS of this newly synthesized drug candidate adopted a unique geometry unlike other derivatives. The aryl arm controls the geometry of the compounds and in the case of **4d** the 2,4-dichlorophenyl moiety allowed the indole and oxindole moieties to occupy space perpendicularly. This unique character, high selectivity and promising activity against three aggressive cancer cell lines of compound **4d** make it a promising anticancer candidate. Therefore, this compound should be considered a potential anti-cancer agent in combination with widely used chemotherapeutic drugs to improve the response of tumors. Currently, a more rigorous *in vivo* study is being undertaken to disclose more preclinical information, such as oral stability, bioavailability, and pharmacokinetics with the anticipation of better activity and high safety margins.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for providing funding to the research group No. (RGP-257).

References

- 1 K. Omori and J. Kotera, *Circ. Res.*, 2007, **100**, 309–327.
- 2 R. Savai, S. S. Pullamsetti, G.-A. Banat, N. Weissmann, H. A. Ghofrani, F. Grimminger and R. T. Schermuly, *Expert Opin. Invest. Drugs*, 2010, **19**, 117–131.
- 3 S.-w. Yang, A. B. Burgin, B. N. Huizenga, C. A. Robertson, K. C. Yao and H. A. Nash, *Proc. Natl. Acad. Sci.*, 1996, **93**, 11534–11539.
- 4 T. S. Dexheimer, S. Antony, C. Marchand and Y. Pommier, *Anti-Cancer Agents Med. Chem.*, 2008, **8**, 381–389.
- 5 E. Bischoff, *Int. J. Impotence Res.*, 2004, **16**, S11.
- 6 C. Lugnier, *Pharmacol. Ther.*, 2006, **109**, 366–398.
- 7 L. Hirsh, A. Dantes, B.-S. Suh, Y. Yoshida, K. Hosokawa, K. Tajima, F. Kotsuji, O. Merimsky and A. Amsterdam, *Biochem. Pharmacol.*, 2004, **68**, 981–988.
- 8 C. Marchand, W. A. Lea, A. Jadhav, T. S. Dexheimer, C. P. Austin, J. Inglese, Y. Pommier and A. Simeonov, *Mol. Cancer Ther.*, 2009, **8**, 240–248.
- 9 G. L. Card, B. P. England, Y. Suzuki, D. Fong, B. Powell, B. Lee, C. Luu, M. Tabrizizad, S. Gillette and P. N. Ibrahim, *Structure*, 2004, **12**, 2233–2247.
- 10 F. Badria, M. Mabeed, W. Khafagy and L. Abou-Zeid, *Cancer Lett.*, 2000, **155**, 67–70.
- 11 F. Badria, M. Mabeed, M. El-Awadi, L. Abou-Zeid, E. Al-Nashar and S. Hawas, *Cancer Lett.*, 2000, **157**, 57–63.
- 12 F. A. Badria, *Cancer Lett.*, 1994, **84**, 1–5.
- 13 A. H. El-Far, F. A. Badria and H. M. Shaheen, *Curr. Drug Discovery Technol.*, 2016, **13**, 123–143.
- 14 M. H. El-Naggar, A. Mira, F. M. A. Bar, K. Shimizu, M. M. Amer and F. A. Badria, *Bioorg. Med. Chem.*, 2017, **25**, 1277–1285.
- 15 S.-E. N. Ayyad, A. Abdel-Lateff, W. M. Alarif, F. R. Patacchioli, F. A. Badria and S. T. Ezmirly, *Environ. Toxicol. Pharmacol.*, 2012, **33**, 245–251.
- 16 M. El-Naggar, F. Abdel-Bar, M. Amer and F. Badria, M. Sc. thesis, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt, 2014.
- 17 A. Barakat, M. S. Islam, A. Majid, A. Mohammed, H. M. Ghawas, F. F. El-senduny, F. A. Badria, Y. A. M. M. Elshaier and H. A. Ghabbour, *US Pat.* 9,822,128, 2017.
- 18 B. Yu, D.-Q. Yu and H.-M. Liu, *Eur. J. Med. Chem.*, 2015, **97**, 673–698.
- 19 M. M. Santos, *Tetrahedron*, 2014, **52**, 9735–9757.
- 20 A. Leoni, A. Locatelli, R. Morigi and M. Rambaldi, *Expert Opin. Ther. Pat.*, 2016, **26**, 149–173.
- 21 L. D. Quin and J. A. Tyrell, *Fundamentals of heterocyclic chemistry: importance in nature and in the synthesis of pharmaceuticals*, John Wiley & Sons, 2010.
- 22 W. Wang and Y. Hu, *Med. Res. Rev.*, 2012, **32**, 1159–1196.
- 23 Y. Zhao, S. Yu, W. Sun, L. Liu, J. Lu, D. McEachern, S. Shargary, D. Bernard, X. Li and T. Zhao, *J. Med. Chem.*, 2013, **56**, 5553–5561.
- 24 S. Edmondson, S. J. Danishefsky, L. Sepp-Lorenzino and N. Rosen, *J. Am. Chem. Soc.*, 1999, **121**, 2147–2155.
- 25 S. M. Rajesh, S. Perumal, J. C. Menéndez, P. Yogeewari and D. Sriram, *MedChemComm*, 2011, **2**, 626–630.
- 26 E. Rajanarendar, S. Ramakrishna, K. G. Reddy, D. Nagaraju and Y. Reddy, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 3954–3958.
- 27 M. A. Ali, R. Ismail, T. S. Choon, Y. K. Yoon, A. C. Wei, S. Pandian, R. S. Kumar, H. Osman and E. Manogaran, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 7064–7066.
- 28 B. Zhang, P. Feng, L. H. Sun, Y. Cui, S. Ye and N. Jiao, *Chem.–Eur. J.*, 2012, **18**, 9198–9203.
- 29 Y. Rew and D. Sun, *J. Med. Chem.*, 2014, **57**, 6332–6341.
- 30 Y. Zhao, L. Liu, W. Sun, J. Lu, D. McEachern, X. Li, S. Yu, D. Bernard, P. Ochsenbein and V. Ferey, *J. Am. Chem. Soc.*, 2013, **135**, 7223–7234.



- 31 G. Lotfy, H. El Sayed, M. M. Said, Y. M. A. Aziz, A. Al-Dhfyan, A. M. Al-Majid and A. Barakat, *J. Photochem. Photobiol., B*, 2018, **180**, 98–108.
- 32 G. Lotfy, M. M. Said, H. El Sayed, H. El Sayed, A. Al-Dhfyan, Y. M. A. Aziz and A. Barakat, *Bioorg. Med. Chem.*, 2017, **25**, 1514–1523.
- 33 A. Barakat, S. M. Soliman, A. M. Al-Majid, M. Ali, M. S. Islam, Y. A. M. M. Elshaier and H. A. Ghabbour, *J. Mol. Struct.*, 2018, **1152**, 101–114.
- 34 H. A. Döndas, M. de Gracia Retamosa and J. M. Sansano, *Synthesis*, 2017, **49**, 2819–2851.
- 35 T. L. Pavlovska, R. G. Redkin, V. V. Lipson and D. V. Atamanuk, *Mol. Diversity*, 2016, **20**, 299–344.
- 36 P. J. Stork and J. M. Schmitt, *Trends Cell Biol.*, 2002, **12**, 258–266.
- 37 Y. Yoshida, K. Hosokawa, A. Dantes, K. Tajima, F. Kotsuji and A. Amsterdam, *Internet J. Oncol.*, 2000, **17**, 227–262.
- 38 K. Hosokawa, D. Aharoni, A. Dantes, E. Shaulian, C. Schere-Levy, R. Atzmon, F. Kotsuji, M. Oren, I. Vlodaysky and A. Amsterdam, *Endocrinology*, 1998, **139**, 4688–4700.
- 39 D. R. Davies, H. Interthal, J. J. Champoux and W. G. Hol, *Structure*, 2002, **10**, 237–248.
- 40 D. R. Davies, H. Interthal, J. J. Champoux and W. G. Hol, *Chem. Biol.*, 2003, **10**, 139–147.
- 41 M. McGann, *J. Chem. Inf. Model.*, 2011, **51**, 578–596.
- 42 P. C. Hawkins, A. G. Skillman, G. L. Warren, B. A. Ellingson and M. T. Stahl, *J. Chem. Inf. Model.*, 2010, **50**, 572–584.
- 43 J. A. Grant, M. Gallardo and B. T. Pickup, *J. Comput. Chem.*, 1996, **17**, 1653–1666.
- 44 J. J. Sutherland, R. K. Nandigam, J. A. Erickson and M. Vieth, *J. Chem. Inf. Model.*, 2007, **47**, 2293–2302.
- 45 T. Mosmann, *J. Immunol. Methods*, 1983, **65**, 55–63.
- 46 T. F. Slater, B. Sawyer and U. Sträuli, *Biochim. Biophys. Acta*, 1963, **77**, 383–393.
- 47 V. U. Ahmad, M. A. Abbasi, H. Hussain, M. N. Akhtar, U. Farooq, N. Fatima and M. I. Choudhary, *Phytochemistry*, 2003, **63**, 217–220.
- 48 <https://www.rcsb.org/structure/1NOP>.
- 49 *VIDA, version 4.1.2*, OpenEye Scientific Software, Santa Fe, NM, USA; <http://www.eyesopen.com>.

